FDA Details Submission Requirements for New Regenerative Advanced Therapy Designation

Drug Industry Daily
A A
The FDA has introduced a new designation for regenerative medicine therapies, laying out the submission requirements for sponsors seeking the expedited review that stems from the 21st Century Cures Act.

To View This Article:

Login

Subscribe To Drug Industry Daily